Cardiac amyloidosis occurs when abnormal proteins accumulate in the heart muscle, causing it to thicken and stiffen, which can eventually lead to heart failure and dangerous rhythm problems. Once considered a rare condition with few options, advances in understanding and treatment now offer patients real hope for managing symptoms, slowing disease progression, and improving quality of life—but early recognition remains crucial.

Understanding Treatment Goals in Cardiac Amyloidosis

When someone receives a diagnosis of cardiac amyloidosis, the journey ahead involves a careful and coordinated approach to care. The main goals of treatment focus on slowing down the buildup of abnormal proteins in the heart, managing symptoms that arise from the stiffened heart muscle, and preventing complications that can threaten life and well-being. These goals matter because cardiac amyloidosis is a progressive condition, meaning it tends to worsen over time if left untreated.^[1]

Treatment strategies depend heavily on several factors, including which type of amyloidosis a patient has, how much protein has already accumulated in the heart, and how well other organs are functioning. The two main types that affect the heart are light-chain amyloidosis (AL), where abnormal proteins come from bone marrow, and transthyretin amyloidosis (ATTR), where abnormal proteins originate in the liver. ATTR can be further divided into hereditary forms, caused by genetic mutations, and wild-type forms, which occur naturally with aging.^[1][2]

Medical societies and expert groups have developed guidelines to help doctors choose the best treatments based on evidence and clinical experience. At the same time, researchers continue to explore new therapies in clinical trials, testing innovative approaches that could offer additional benefits. For many patients, the difference between older treatments and newer options has been life-changing. Just a decade ago, cardiac amyloidosis was often considered untreatable beyond symptom relief. Today, disease-specific medications can target the underlying cause, offering patients longer and better lives.^[8][12]

Standard Treatment Approaches

Managing AL Amyloidosis

Light-chain amyloidosis requires treatment aimed at the bone marrow, where abnormal plasma cells produce the harmful light-chain proteins. The standard approach uses chemotherapy medications similar to those used for certain blood cancers. These drugs work by targeting and destroying the plasma cells that manufacture the misfolded proteins. Common chemotherapy agents include bortezomib, which belongs to a class called proteasome inhibitors, and daratumumab, a type of immunotherapy that helps the immune system attack abnormal cells.^[7][8]

Other medications used in AL treatment include cyclophosphamide, dexamethasone, and drugs called immunomodulatory agents such as lenalidomide and pomalidomide. These medications are often combined in specific regimens designed to maximize effectiveness while managing side effects. The combinations chosen depend on how advanced the disease is, how well the heart and kidneys are functioning, and how strong or frail the patient is overall.^[8]

For some patients with AL amyloidosis who are healthy enough and whose disease hasn’t progressed too far, doctors may recommend autologous stem cell transplantation. This procedure involves collecting the patient’s own stem cells, then using high-dose chemotherapy to eliminate abnormal plasma cells, followed by returning the collected stem cells to help the bone marrow recover. While this approach can be very effective, it requires careful patient selection because the intensive treatment puts significant stress on the heart and other organs.^[8]

The duration of chemotherapy treatment varies. Some patients receive several months of initial therapy followed by maintenance treatment to keep the disease under control. Regular monitoring with blood tests measuring light-chain proteins helps doctors determine whether the treatment is working and when adjustments might be needed.

Managing ATTR Amyloidosis

Treatment for transthyretin amyloidosis takes a completely different approach because the problem originates in the liver, not the bone marrow. The liver produces a protein called transthyretin that normally carries thyroid hormone and vitamin A through the bloodstream. In ATTR amyloidosis, this protein becomes unstable, breaks apart, and forms amyloid deposits.^[3]

The primary medication approved for ATTR cardiac amyloidosis is tafamidis, marketed under the names VYNDAQEL and VYNDAMAX. Tafamidis works as a protein stabilizer—it binds to the transthyretin protein and prevents it from breaking apart and forming amyloid fibrils. Clinical trials showed that tafamidis significantly reduces disease progression and mortality in patients with ATTR cardiac amyloidosis. This medication was approved in 2019 and represents the first disease-modifying therapy specifically for this condition.^[12]

Another stabilizer called acoramidis has also been developed and works through a similar mechanism, helping keep the transthyretin protein in its stable form. Additionally, diflunisal, an older anti-inflammatory drug, has some protein-stabilizing effects and is sometimes used off-label for ATTR amyloidosis, though it can have side effects and isn’t suitable for everyone.^[12]

These medications are typically taken daily for the long term. The goal is ongoing stabilization rather than a cure. Patients continue treatment indefinitely as long as they tolerate the medication and it continues to provide benefit.

Treating Heart Failure Symptoms

Regardless of which type of amyloidosis someone has, managing heart failure symptoms is an essential part of care. As amyloid proteins stiffen the heart muscle, patients often develop fluid buildup in the legs, abdomen, and lungs, along with shortness of breath and fatigue.^[1]

Diuretics, often called “water pills,” help remove excess fluid from the body by increasing urine production. These medications can significantly relieve swelling and breathing difficulties. However, doctors must carefully balance diuretic doses because patients with cardiac amyloidosis can be sensitive to fluid shifts and blood pressure changes.^[15]

Managing irregular heart rhythms is also important. Many patients with cardiac amyloidosis develop atrial fibrillation, an irregular heartbeat that can cause palpitations and increase stroke risk. Medications to control heart rate or rhythm may be prescribed, along with blood thinners to prevent clots. Some patients may need a pacemaker if the disease affects the heart’s electrical system and causes dangerously slow heart rates.^[1]

Doctors approach other standard heart failure medications with caution in cardiac amyloidosis. Some common drugs like ACE inhibitors, ARBs, and certain beta-blockers may not be well tolerated because they can lower blood pressure too much in patients whose hearts are already stiff and unable to fill properly. Each medication decision requires individualized assessment.

Common Side Effects of Standard Treatment

Chemotherapy for AL amyloidosis can cause various side effects including fatigue, increased infection risk due to lowered immune function, numbness or tingling in hands and feet (peripheral neuropathy), nausea, diarrhea, and low blood cell counts. The intensity and type of side effects vary depending on which drugs are used and how each patient’s body responds.^[8]

Tafamidis and other ATTR stabilizers tend to be better tolerated with fewer side effects compared to chemotherapy. However, patients may still experience issues, and regular monitoring remains important to ensure the medications are working safely.

Diuretics can cause dehydration, low blood pressure, electrolyte imbalances, and increased urination that disrupts daily activities. Finding the right dose requires ongoing communication between patients and their care teams.

Innovative Treatments in Clinical Trials

Gene Silencing Therapies for ATTR

One of the most promising areas of research involves stopping the liver from producing transthyretin protein altogether. Several medications use advanced techniques to “silence” the gene that tells liver cells to make this protein. These approaches work at the genetic level, preventing the problem before it starts.^[8]

Patisiran and inotersen are two gene-silencing medications that have been studied in clinical trials. Patisiran uses small pieces of genetic material called small interfering RNA (siRNA) to block the production of transthyretin. It’s delivered through intravenous infusion every three weeks. Inotersen uses a different technology called antisense oligonucleotides and is given as a weekly injection under the skin. Both medications dramatically reduce the amount of transthyretin protein in the bloodstream.^[8][12]

Clinical trials of these gene-silencing agents initially focused on patients with hereditary ATTR who had nerve damage (neuropathy). Results showed improvements in nerve function and quality of life. Researchers are now studying whether these medications also benefit patients with ATTR cardiac amyloidosis. Early findings suggest they may help slow heart disease progression when the cardiac involvement isn’t too advanced.^[12]

These trials typically enroll patients in Phase II, which tests whether the medication is effective, and Phase III, which compares the new treatment against standard care or placebo in larger groups. Trial locations include major medical centers across the United States, Europe, and other regions. Eligibility criteria usually require confirmed ATTR amyloidosis with specific levels of heart involvement that aren’t too severe.

Medications That Remove Existing Amyloid Deposits

While stabilizers and silencers prevent new amyloid formation, researchers are also developing treatments that could actually remove deposits that have already accumulated in the heart. These “depleter” therapies represent an exciting frontier because they might reverse some damage rather than just slowing progression.^[8][12]

One approach involves antibodies designed to recognize and bind to amyloid fibrils. The immune system can then clear away the antibody-coated amyloid deposits. Several experimental antibodies are being tested in clinical trials, though specific names and codes vary as research evolves. Another strategy uses medications that break down the structure of amyloid fibrils, making them easier for the body to remove naturally.^[12]

These treatments are mostly in early-phase trials (Phase I for safety and Phase II for preliminary effectiveness). Researchers measure whether amyloid deposits in the heart decrease using specialized imaging tests. They also track improvements in heart function through echocardiograms and other assessments, along with monitoring symptoms and quality of life.

The preliminary results from some trials have shown promise, with evidence that certain patients experience reduced amyloid burden and stabilized or improved heart function. However, these treatments remain experimental, and researchers continue gathering data on optimal dosing, which patients benefit most, and long-term outcomes.

Advanced Therapies for AL Amyloidosis

For light-chain amyloidosis, researchers continue developing more effective and better-tolerated chemotherapy combinations. Daratumumab, a monoclonal antibody that targets a protein called CD38 on plasma cells, has shown particular promise. When added to standard chemotherapy regimens, daratumumab improves response rates, helping more patients achieve very low levels of harmful light chains. This medication is now commonly used in clinical practice, though trials continue exploring optimal combinations and sequences.^[8]

Other experimental approaches for AL include newer immunotherapy drugs that help the immune system recognize and destroy abnormal plasma cells more effectively. Some trials also investigate whether medications that remove existing AL amyloid deposits could benefit patients whose light-chain production has been controlled but who still have significant protein buildup in their heart.

Trial Participation Considerations

Clinical trials offer access to cutting-edge treatments that aren’t yet widely available. For patients whose disease isn’t well controlled with standard therapies, or who want to contribute to advancing medical knowledge, trial participation can be valuable. Trials are conducted at specialized centers with expertise in cardiac amyloidosis, often academic medical centers and large hospital systems.^[10]

Eligibility requirements vary by study but typically include confirmed diagnosis of a specific type of cardiac amyloidosis, certain levels of organ function, and absence of other conditions that might interfere with the study. Some trials focus on patients with early disease, while others target those with more advanced conditions. Patients interested in trials should discuss options with their cardiologist or seek evaluation at an amyloidosis specialty center.

The Role of Transplantation

For patients with end-stage cardiac amyloidosis who don’t respond adequately to other treatments, heart transplantation may be considered. This major surgery involves replacing the diseased heart with a healthy donor heart. For patients with AL amyloidosis, transplantation is complex because the underlying bone marrow disorder must also be treated to prevent amyloid from building up in the new heart.^[8]

In hereditary ATTR amyloidosis, some patients may be candidates for liver transplantation or combined heart-liver transplantation. Because the liver produces the abnormal transthyretin protein in hereditary forms, replacing the liver can eliminate the source of the problem. Combined transplants are highly specialized procedures performed at only a few centers with extensive expertise.^[8]

Transplant evaluation is rigorous and considers many factors including age, overall health, presence of other organ damage, and availability of donor organs. Not everyone is a suitable candidate, but for those who are, transplantation can be life-saving.

Most Common Treatment Methods

• Chemotherapy and Immunotherapy
  • Proteasome inhibitors like bortezomib target abnormal plasma cells in AL amyloidosis
  • Daratumumab, a monoclonal antibody, enhances immune system attack on plasma cells
  • Cyclophosphamide, dexamethasone, lenalidomide, and pomalidomide used in combination regimens
  • Autologous stem cell transplantation for selected AL patients who are healthy enough to tolerate intensive treatment
• Protein Stabilizers
  • Tafamidis (VYNDAQEL, VYNDAMAX) binds to transthyretin protein and prevents it from breaking apart in ATTR amyloidosis
  • Acoramidis works through similar stabilization mechanism
  • Diflunisal, an anti-inflammatory drug with protein-stabilizing effects, used in some cases
  • These medications are taken daily on an ongoing basis
• Gene Silencing Agents
  • Patisiran uses siRNA technology to block transthyretin production in the liver
  • Inotersen uses antisense oligonucleotides for similar gene-silencing effect
  • Delivered through infusions or injections on regular schedules
  • Studied primarily in patients with hereditary ATTR, now being evaluated for cardiac involvement
• Amyloid Depletion Therapies
  • Experimental antibodies that target and remove existing amyloid deposits
  • Medications that break down amyloid fibril structure
  • Currently in early-phase clinical trials at specialized centers
  • Aim to reverse rather than just prevent amyloid accumulation
• Heart Failure Management
  • Diuretics to remove excess fluid and reduce swelling
  • Medications to control abnormal heart rhythms like atrial fibrillation
  • Blood thinners to prevent stroke in patients with rhythm problems
  • Pacemakers or implantable defibrillators for electrical system problems
  • Careful blood pressure management with individualized medication selection
• Transplantation
  • Heart transplantation for end-stage disease in carefully selected patients
  • Liver transplantation for hereditary ATTR to eliminate source of abnormal protein
  • Combined heart-liver transplantation in specialized centers
  • Requires comprehensive evaluation and ongoing monitoring after surgery